BACE1 and Alzheimer disease: Notably, RA-PYD and RA-NAP exhibited comprehensive biological activities, including antioxidant, anti-inflammatory, BACE-1 inhibitory, and anti-tau aggregation effects, highlighting their potential as multi-target agents for AD therapy.